Everest Medicines announced that its licensing partner NovaBridge Biopharma and subsidiary Visara. reported positive topline results from a Phase 2a clinical study of VIS‑101, an investigational tetravalent, dual VEGF‑A × ANG‑2 inhibitor for retinal vascular diseases, including wet age‑related macular degeneration (wet AMD).
The randomized Phase 2a study (NCT05456828) enrolled 38 patients in China across 3 mg and 6 mg dose cohorts. Topline data showed mean improvements in Best Corrected Visual Acuity (BCVA) exceeding 10 ETDRS letters and median central subfield thickness (CST) reductions between 100 and 150 μm. About two‑thirds of patients remained retreatment‑free for four months, and roughly half for six months, suggesting potentially best‑in‑class durability. VIS‑101 was well tolerated with no dose‑limiting toxicities reported.
According to Everest CEO Rogers Yongqing Luo, the results underscore the potential of dual VEGF‑A/ANG‑2 inhibition to extend treatment durability while maintaining strong efficacy. Everest holds the exclusive license to develop and commercialize VIS‑101 in Greater China, South Korea, Singapore, and select Southeast Asian markets under a 2025 agreement with Visara.
NovaBridge Executive Chairman Emmett T. Cunningham, Jr. said the data validate VIS‑101’s design and provide proof‑of‑concept for advancing its development. A Phase 2b dose‑determining study is planned for the second half of 2026, followed by a global Phase 3 program in 2027. Wet AMD affects an estimated 20 million people globally, highlighting the ongoing need for more durable therapeutic options.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!